CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 420 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,956 | -19.1% | 682 | 0.0% | 0.02% | -14.8% |
| Q2 2023 | $38,287 | +9.6% | 682 | -11.7% | 0.03% | +3.8% |
| Q1 2023 | $34,918 | +11.3% | 772 | 0.0% | 0.03% | +8.3% |
| Q4 2022 | $31,382 | -37.2% | 772 | 0.0% | 0.02% | -40.0% |
| Q3 2022 | $50,000 | +4.2% | 772 | 0.0% | 0.04% | +48.1% |
| Q1 2022 | $48,000 | +50.0% | 772 | +80.4% | 0.03% | +58.8% |
| Q4 2021 | $32,000 | -33.3% | 428 | 0.0% | 0.02% | -39.3% |
| Q3 2021 | $48,000 | -30.4% | 428 | 0.0% | 0.03% | -26.3% |
| Q2 2021 | $69,000 | +32.7% | 428 | 0.0% | 0.04% | +18.8% |
| Q1 2021 | $52,000 | – | 428 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |